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ABSTRACT: The effectiveness of an imaging technique not only depends on its ability to 
image quantitatively both morphological and physiological functions of the tissue, but also 
on the contrast agent used to communicate with biomolecules. Several types of contrast 
media are used in medical imaging and they can roughly be cataloged based on the 
imaging modalities where they are used. More importantly, the use of contrast agent with 
their size ranging in nanometer scale has become general practice in medical diagnosis. As 
the matter of fact, nanoparticles have fascinated scientist for over a century and are now 
heavily utilized in biomedical sciences and engineering as they are long known to 
communicate effectively with the biomolecules. Today these materials can be synthesized 
and modified with various chemical functional groups which allow them to be conjugated 
with antibodies, ligands, and drugs of interest and thus opening a wide range of potential 
applications in biotechnology, and more importantly in diagnostic medical imaging via 
ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron 
emission tomography (PET). These imaging modalities differ not only in resolution, but 
also in the instrumentation and the type of nanoparticle that can be employed as its 
assistant.  Of these imaging techniques, ultrasound is one of the oldest imaging modality 
which is still widely used to examine internal organs of the body and diagnose potential 
disease states such as cancer, plague, clots, and swelling.  Various articles have been 
published over the period of years detailing the instrumentation and the applications of 
ultrasonography, but very few have emphasized the importance of particle size in 
developing a successful contrast agent for ultrasonography.  Thus in the present review 
article we aim to present the basic principles involved in developing successful contrast 
agent for Ultrasound imaging. Furthermore, we have also discussed the experimental and 
physical aspects of various types of nanoparticles including its fabrication and design of 
targeted contrast agents. Finally, we have cited some of the best biomedical and clinical 
applications of the developed nanoprobes and their use for Ultrasound imaging. 
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INTRODUCTION
ᴪ 
 
The ultrasound (US) imaging also called ultrasound 
scanning, sonorgaphy, or ultrasonography uses the 
sound waves to form images of soft tissues in the 
body. These sound waves typically generated by a 
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quartz crystal are reflected at the interfaces between 
different tissues due to differences in the 
mechanical properties of the tissues. The 
transmission and reflection of these high-frequency 
waves are then displayed with different types of US 
modes. The speed at which these reflected waves 
propagates in tissues and its time of reflection can 
be converted into distance of reflection. Hence with 
the higher frequencies of the sound waves, the 
absorption of the sound beam by the medium is 
also higher and better is the image resolution. 
Higher frequency sound waves are used to provide 
good detail of superficial organs such as the breast, Mody et al / Nanoparticles in Diagnostic Imaging 
9 
Copyrighted © by Dr. Arun Kumar Agnihotri. All right reserved 
 
whereas the lower frequency sound waves are used 
for examinations of the abdomen. In general, there 
are various types of US techniques that are 
typically used for biomedical imaging some of 
which are, brightness-mode (B mode), spectral 
doppler, color doppler and 3D US. Even with these 
advances in the imaging techniques, the US is 
unable to differentiate between tissues with similar 
acoustical properties. To address these challenges, 
US contrast agents (USCA) have been developed to 
artificially change the reflection coefficient 
between the two tissues; thus enhancing the 
backscattered signal and improving the image 
contrast. 
The field of diagnostic ultrasound is again on the 
cusp of major change with the advent of contrast 
agents available for variety of clinical applications. 
In the last decade, major pharmaceutical 
companies, ultrasound scanner manufacturers, and 
biomedical investigators have invested manpower 
and funding in developing efficacious ultrasound 
contrast agents and new contrast-specific imaging 
modalities. They have made extensive use of 
solids, gases and liquids contrast agents in an 
attempt to discover novel USCA suitable for 
particular diagnostic purpose. The contrast agents 
based on solids, liquids or gases can improve the 
image quality of sonography either by decreasing 
the reflectivity of the undesired interfaces or by 
increasing the backscattered echoes from the 
desired regions.
1 In the former approach, the 
contrast agents are taken orally, and in the latter 
one, the agent is introduced vascularly. However, 
the contrast enhancing effect of the type of 
materials is regulated via three main phenomena 
namely, backscattering, beam attenuation, and 
difference in speed of the sound. 
The term "backscattering" refers to the 
phenomenon in which energy (ultrasound energy in 
this case) is scattered back towards the source by a 
scatterer with certain physical properties. Based on 
the physical characteristics of the scatterer, the 
scatterer with larger diameter will scatter a greater 
amount of the ultrasound wave than a smaller 
substance. Furthermore, the capability of a 
substance to backscatter ultrasound energy also 
depends upon its compressibility (κs). These two 
physical properties; the particle size and κs, can be 
considered in tandem when examining different 
substances to measure its ability as a good 
scatterer. In other words, it is useful to compare 
"scattering cross-section of the scatterer” which is 
one particular measure of the ability of a substance 
to cause backscattering. 
The scattering cross-section of a small scatterer, s, 
can be determined by a known equation: 
  
 
Where, K = 2π/λ, where λ is the wavelength; a = 
the radius of the scatterer; κs  = adiabatic 
compressibility of the scatterer; κ = adiabatic 
compressibility of the medium in which the 
scatterer exists, ρs = density of the scatterer and, ρ = 
the density of the medium in which the scatterer 
exists. 
This equation can serve as a valuable tool in 
evaluating the utility of different substances as 
image contrasting agents. The first bracketed 
quantity in the above equation can be assumed to 
be constant for the purpose of comparing solid, 
liquid and gaseous scatterers. Now for the purpose 
of medical imaging, it can be assumed that the 
compressibility of a solid particle is much less than 
that of the surrounding medium, whereas, the 
density of the particle is greater. Similarly, for a 
“pure liquid” scatterer, the adiabatic 
compressibility and density of the scatterer ρs are 
likely to be approximately equal to the surrounding 
medium  ρ. Hence, from the above equation, the 
liquids would have a scattering cross-section of 
zero. In reference to the above equation and the 
following idea, pure liquids are relatively 
inefficient scatterers. 
Moreover, the scattering cross-section of a gas is 
substantially different than a liquid or solid, in part, 
because a gas bubble can be compressed to a 
greater degree than a liquid or solid. To add, free 
gas bubbles in a liquid exhibit oscillatory motion at 
a frequency near that of the ultrasound waves 
commonly used in medical imaging. As a result, 
the scattering cross-section of a gas bubble can be 
over a thousand times larger than its physical size. 
Therefore, it is recognized that gas bubbles are 
superior scatterers of ultrasound energy than solid 
and liquid scatters. 
In spite of the known advantages, the rapid 
dissolution of free gas bubbles in solutions such as 
blood or many aqueous intravenous solutions, 
severely limits their use as an ultrasound contrast-
enhancing agent. The most important limitations 
are the size of the microbubble and the length of 
time for which a microbubble will exist before 
dissolving into the solution. Examining the size 
requirements for microbubbles more closely, the 
gas bubbles must, of course, be sufficiently small 
that a suspension of the bubbles does not carry the 
risk of embolism to the organism in which they are 
infused. At the same time, extremely small free gas 
bubbles composed of the gases generally used in 
ultrasound contrast imaging, dissolve into solution 
so rapidly that their image-enhancing capability 
exists only in immediate proximity to the infusion 
site. 
Ideally, the contrast agents circulating in the 
vasculature should be less than 8￿m in diameter so 
that they can pass through the pulmonary bed of the 
lungs, allowing for imaging in both the venous and 
arterial vessels.
2 To penetrate beyond the Mody et al / Nanoparticles in Diagnostic Imaging 
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vasculature, the agents need to be over an order of 
magnitude smaller, in the nm range. If this can be 
achieved, it opens up the possibility of targeting 
areas such as tumors and inflammation. The tumors 
will not survive unless supported by blood supply. 
The blood vessels in tumors are characterized by 
irregular diameters and ill defined structures with 
the reported pore cut-off size between 380-780nm 
for depending on the type of tumor being analyzed, 
its location and relative diameter. In fact, 
nanoparticles up to 700 nm have been observed 
passing through capillary walls in inflamed vessels 
and in tumors.
3 Although the imaging and drug 
delivery aspects of a nanosize USCA are evident, it 
is less clear that a nano agent is acoustically 
realistic. According to the equation the scattering 
cross-section for a single bubble, σ, is proportional 
to the sixth power of the radius. A drop in diameter 
with an order of magnitude would lower σ by six 
orders of magnitude. In addition, the bubble 
resonance frequency is inversely proportional to the 
diameter; this would require the use of unusually 
high frequency transducers for imaging 
applications with nanobubbles. Although recently a 
40 MHz intravascular transducer with lateral 
resolution of 0.5 mm has been manufactured, the 
commercial applications of the nanosized bubbles 
as USCA have still to be evaluated.
4, 5 
Image contrast has also been observed in 
conventional imaging due to localized beam 
attenuation of the sound waves owing to the 
differences between certain tissues. Measurement 
of the attenuation contrast caused by microspheres 
containing gas microbubbles and solid particles has 
been accomplished. The contrast enhancement 
from the use of these particles is also attributed to 
the attenuation of the ultrasound wave generated 
from the presence of dense particles in a soft 
medium which absorbs energy by a mechanism 
referred to as "relative motion." The change in 
attenuation caused by relative motion can be shown 
to increase linearly with particle concentration and 
as the square of the density difference between the 
particles and the surrounding medium. Therefore, 
where substantial accumulation of solid particles 
occurs, attenuation contrast may be a viable 
mechanism for observing image contrast 
enhancement. This phenomenon acts as the basic 
principle behind the nano sized targeted USCA. 
However, techniques based on attenuation contrast 
as a means to measure the contrast enhancement of 
a liquid agent are not well-developed and, even if 
fully developed, may suffer from limitations as to 
the internal organs or structures with which this 
technique can be used. For example, it is unlikely 
that a loss of attenuation due to liquid contrast 
agents could be observed in the image of the 
cardiovascular system because of the high volume 
of liquid contrast agent that would need to be 
present in a given vessel before a substantial 
difference in attenuation could be measured. 
An additional possible technique to enhance 
contrast in an ultrasound image has been proposed 
based on the fact that the speed of sound varies 
depending on the media through which it travels. 
Therefore, if a large enough volume of an agent is 
infused into a target area then the speed of sound is 
into the infused area different than the surrounding 
tissue. This difference in the speed of sound 
through the target area may be measurable. 
Presently, this technique is only experimental. 
Therefore, considering the three techniques 
described above for contrast enhancement in an 
ultrasound image, the marked increase in 
backscatter caused by free gas microbubbles is the 
most dramatic effect and contrast-enhancing agents 
that take advantage of this phenomenon would be 
the most desirable if the obstacle of their limited 
stability in solution could be overcome. 
 
GAS BUBBLES AS USCA 
 
As discussed in the previous section small bubbles 
are readily detected in an image produced using 
standard ultrasound imaging techniques. But the 
history of small bubbles as USCA can be traced 
back to 1968, when Dr Charles Joiner, a 
cardiologist, made an accidental observation while 
he was performing M-mode echocardiogram by 
injecting a patient with indocyanine green through 
a left ventricular catheter, to measure cardiac 
output.
6 During his measurements he observed an 
increase in the US signal after each injection. 
Consequent research showed that the increase was 
caused by small bubbles forming at the catheter tip. 
However, the use of these contrast agents was 
seriously hindered as their effects were transient 
and could not be successfully repeated. These 
features limited their clinical use but subsequent 
research permitted the use of small bubble contrast 
agents in clinical practice. Since then various filling 
gas such as nitrogen, perfluorocarbons, and sulfur 
hexafluoride has been used as microbubble which 
carried a particle size of 1-5 microns. In practical, a 
small amount of the suspended contrast agent 
(ranging from microliters to milliliters) is injected 
intravenously during an ultrasonic exam.
7 
However, the collapse of the microbubble and the 
rapid formation (due to the coalesce of smaller 
particles) when exposed to US are some of the 
other side affects observed after on the usage of 
these contrast agents. This has also led to various 
innovative systems such as shell coated 
microbubble which can increase the stability of 
microbubble under the operating condition. The 
shell loaded with microbubble is designed to 
reduce diffusion of the bubble into the blood and 
increase it stability and the dissociation from strong 
ultrasonic waves. The outer coating of shell can be Mody et al / Nanoparticles in Diagnostic Imaging 
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stiff (e.g., albumin) or more flexible 
(phospholipid), with the shell thickness in the range 
of 10-200 nm. In fact, Feinstein was the first to find 
that albumin was capable of improving 
microbubble stability and its size can be controlled 
by sonication. This leads to the first pharmaceutical 
echo-enhancer, Albunex™, by Molecular 
Biosystems (San Diego, CA, USA) but is no longer 
in production.
8, 9 These encapsulated microbubbles 
are highly echogenic due to differences in their 
compressibility (k) and density (￿), compared to 
tissue or plasma. The compressibility of air is 7.65 
× 10
-6 m
2/N, in comparison with 4.5 × 10
-11 m
2/N 
for water (on the same order of magnitude as tissue 
and plasma).[10] The compressibility for an 
encapsulated microbubble falls within this range, as 
De Jong predicts the compressibility of Albunex™ 
to be 5 × 10
-7 m
2/N.
10, 11 This impedance mismatch 
results in a very high echogenicity, such that the 
echo from an individual contrast agent can be 
detected by a clinical ultrasound system. The 
research work over the period of year gave rise to 
various clinically used USCA such as Levovist™, 
Echovist™, EchoGen® (Abbot Laboratories, 
Chicago, IL, USA), Sonovue™ (BR 1 Bracco, 
Milan, Italy), Aerosomes™ (ImaRx, Tucson, AZ, 
USA), Sonovist™ (Schering AG, Berlin, Germany) 
are been currently marketed and clinically used. 
Two agents containing perfluoropropane are 
currently approved in the United States for use in 
cardiology: Optison® (Mallinckrodt Inc., St. Louis, 
MO), with a denatured albumin shell, and 
Definity® (Bristol-Myers Squibb Medical Imaging, 
Inc., Billerica, MA), with a phospholipid shell. 
However, this micron sized USCA limits their use 
as the intravascular contrast agent suited to 
targeting cells outside the capillary vasculature, 
such as cancer cells.  This can be well achieved by 
nanosized USCA which are also likely to circulate 
within the human body for a reasonable length of 
time, providing a greater time window for imaging. 
This offers an advantage over larger sized contrast 
agents (>1 μm diameter), which are cleared rapidly 
by the body's reticuloendothelial system following 
injection into the bloodstream. Moreover, these tiny 
bubbles have short life time due to the high gas 
pressure caused by the surface tension. For the 
utilization of the nanobubbles they have to be some 
how stabilized so as to increase its lifetime. A 
surfactant, electrolyte or lipid which can cover the 
nanobubble could reduce the surface tension, and 
the diffusion of the nanobubble to the surrounding 
liquid. In addition to the stability of the 
nanobubbles, the decrease in the size of the bubble 
leads to decrease in its echogenicity which further 
decrease its use as the potential USCA. But many 
research articles have been proposed to increase its 
stability and its echogenicity so as to enable their 
use in medical imaging to its utmost potential.  
Present nanomolecular ultrasonographic contrast 
agents are mostly encapsulated perfluorocarbon in 
a polymer or a liquid shell as shown in figure 1.
12 
Being intravascular most of its potential 
applications are concentrated on diseases in which 
blood vessels are involved,
  such as thrombus 
generation, inflammation, and tumor growth. To 
increase the stability of these nanoformulations 
these intravascular USCA against dissolution and 
coalescence they are encapsulated with an elastic 
solid shell which can support a strain to counter the 
effect of surface tension. In other cases, the 
material is a surfactant, or a combination of two or 
more surfactants. They promote stability by greatly 
reducing the surface tension at the interface. Even 
though, sulfur hexafluoride, nitrogen, and 
perfluorochemicals are used as microbubble-filling 
gases, most newer nano sized USCA use 
perfluorochemicals because of their low solubility 
in blood and high vapor pressure. By substituting 
different types of perfluorocarbon gases for air, the 
stability and plasma longevity of the USCA have 
been markedly improved, usually lasting more than 
five minutes.
13 
 
 
 
Figure 1: Nano/microcapsules with a single core of liquid perfluorocarbons within a 
biodegradable polymeric shell of homogeneous thickness. Copyrighted from reference
12. 
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DEVELOPMENT OF NANOBUBBLES 
 
Of various methods available for the synthesis of 
nanobubbles, Masato and coworkers successfully 
developed nanobubbles using Shirasu-porous-glass 
(SPG) membranes with uniform pores in a system 
composed of dispersed gaseous and continuous 
water phases containing sodium dodecyl sulfate 
(SDS) as a surfactant. On pressuring air in SDS, 
monodispersed nanobubbles with a mean bubble 
diameter of 360–720 nm, were stably produced.
14 
Also, stable nanobubbles with effective diameters 
of several hundreds nanometer were developed 
when an aqueous solutions were sonicated with a 
palladium electrode. This method is versatile in 
obtaining bubbles of different sizes, as the size of 
the nano bubbles could be varied with varying 
amount of the salts and surfactants.
15 
Even though the development of nanobubbles is 
long known, Oeffinger and Margaret pioneered the 
development of a surfactant stabilized nanosized 
USCA filled with perfluorocarbon gas. The ST68 
surfactant (Span 60 and Tween 80) stabilized 
nanometer-sized, USCA were developed via 
differential centrifugation. The centrifugation at 
300 rpm for 3 min produced USCA with a mean 
diameter of 450 nm as measured by dispersive light 
scattering. Further, while the imaging studies with 
these nanoshells produced an enhancement of 25.5 
dB in vitro, they produced excellent power Doppler 
and grey-scale pulse inversion harmonic images at 
low acoustic power when administered in rabbits as 
shown in figure 2.  Infact, in vivo dose-response 
curves (not shown) obtained in three rabbits also 
showed enhancement between 20 and 25 dB for 
dosages above 0.025 mL/kg.obtained with the 
particle Still, the echogenicity recorded for these 
USCA was quite low as compared to the 1.4￿m 
sized ST68 (35 dB). This reduction in echogenicty 
is attributed to the smaller size of the USCA.
2, 16 
Similar to the surfactant stabilized nanoparticles, 
MRX-15 developed by ImaRx Therapeutics 
(Richmond, WA) is the next generation of lipid 
coated, perfluorocarbon filled nanobubbles which 
are being evaluated in clinical trials for the
 
dissolution of blood clots in ischemic stroke and 
other vascular
 occlusions. Due
 to their small size 
and their relation to USCA their progress can be 
monitored on diagnostic ultrasound. 
 
 
 
Figure 2: Power Doppler image of New Zealand rabbit right kidney, (a) preinjection; (b) postinjection of 
0.1 mL/kg of ST68-N (3 min at 300 RPM). Arrows indicate kidney capsule. Copyrighted from reference
2 
 
In another study, Wheatley et al has also developed 
Poly (D,L-Lactic acid)/camphor based USCA   
which encapsulates sulfur hexafluoride gas (SF6), a 
hydrophobic and biocompatible inert gas to 
enhance the backscattered signals.  Camphor was 
used to render Poly(D,L-Lactic acid) nanoparticles 
hollow, also acting as the plasticizer for efficient 
gas introduction.  While the camphor was removed 
during the lypholization, the SF6 stayed 
encapsulated and hence enhancing the acoustic 
property. These particles obtained were spheroidal 
in shape with the mean diameter of 200 nm as 
measured by DLS. On isonating the nanoparticles 
encapsulated with SF6, they showed an 
enhancements of 7.5dB over the background dose 
of 0.35 mg/mL.
17 
Another novel class of nano/microbubble 
irreversible switch is also developed by Natalya 
Rapoport and co workers. The phase state and sizes 
of these nanoparticles were sensitive to the 
copolymer/perfluorocarbon
  volume ratio. At 
physiological temperatures the nanodroplets 
coalesce and are converted
 into nano/microbubbles 
which can further act as better imaging probe due 
to increase in particle size. On injection into mice 
the nanobubbles extravasated from the blood 
vessels surrounding the tumors,
 selectively into the 
tumor interstitium,  These nanoparticles then 
coalesce into larger microbubbles, which were 
visible using standard ultrasound imaging 
instruments. Focused ultrasound is then directed at 
the tumors, triggering drug release within the 
tumors for its therapeutic effect.
18, 19 Mody et al / Nanoparticles in Diagnostic Imaging 
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Even with the use of the nanobubbles the safety of 
microbubbles and nanomolecules needs to be 
considered
 briefly. USCA being foreign chemical 
the intrinsic side
 effects, and also
 the potential for 
enhanced bioeffects caused by the ultrasound
 wave 
itself have to be considered. Some mild side effects 
have
 been described for perfluorochemicals: mild 
allergy symptoms
  and increased liver enzymes
20 
and trembling, mild fever, and
 low back pain.
21 In 
addition,  the vascular damage has also been 
described in
  animals in vivo in the lungs,
22 the 
bowels,
23, 24 and the kidneys
25. Therefore,
 extreme 
caution should be exercised before UCM are 
introduced
 in obstetric ultrasonography. 
 
SOLID NANOPARTICLES AS USCAS 
 
It has been reported that solid nano-sized particles 
could, in theory, be a better ultrasound contrast 
material than nanobubbles owing to the acoustic-
impedance mismatch between solids and soft 
tissue.
26 Jun Liu and co workers have investigated 
the effect of solid silica nanospheres for enhancing 
ultrasonic grey scale images in tissue phantoms and 
mouse livers in vivo.
27 The image brightness of 
mouse livers increased following particle 
administration suggesting that it is feasible to use 
solid nanoparticles as contrast enhancing agents for 
ultrasonic imaging. Unfortunately, to date, the 
development of nanoparticulate contrast agents has 
concentrated mainly on MRI. 
TARGETED CONTRAST AGENT 
 
Various tissue targeted USCA has been developed 
over the period of time using both gas encapsulated 
nanoparticles and solid nanoparticles. Moreover, 
one of the first ultrasonographic applications of the 
targeted USCA was detection
  of fibrin thrombi. 
Herein, the USCA were composed of the lipid 
encapsulated non gaseous, perfluorocarbon 
emulsion that utilizes a triphasic targeting approach 
based upon the interaction of avidin and biotin 
molecules as shown in figure 3.
28-30 These acoustic 
particles were approximately 250 nm in diameter 
with inherently low acoustic reflectivity when free 
in suspension, but significantly increase the 
acoustic backscatter when bound to a surface.  The 
ligand-avidin- contrast targeted contrast system 
used in conjunction with high-frequency ultrasound 
(30 to 50 MHz) demonstrated the feasibility of the 
novel USCA for the detection of targeted pathology 
with intravascular ultrasonic catheters. While, the 
increases in backscattered power of approximately 
6 dB were found for the biotinylated, the 
intravascular ultrasonic images (30 MHz nominal 
center frequency) of plasma clots after exposure to 
the targeted contrast agent were brighter 0, < 0.05) 
than controls. These results demonstrated the first 
high-frequency acoustic enhancement with a novel 
targeted contrast agent. 
31 
 
 
 
Figure 3: Microbubble with bioconjugates attached. The enlarged view shows the 
anchor, tether and ligand. Copyrighted from reference 
32 
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Similarly, solid nanoparticulate USCA developed 
from a biodegradable polymer, polylactic acid 
(PLA) (mean diameter = 250 nm) surface 
conjugated to an anti-Her2 antibody (i.e., 
Herceptin) for specific binding to breast cancer 
cells that overexpress Her2 receptors has been 
developed by Jun et al.
27  Figure 4, shows the 
synthetic scheme for the preparation of USCA from 
biodgradable PLA and surface conjugated to anti-
Her2 antibodies. These synthesized particles were 
examined for target specific binding and the 
resultant ultrasound enhancement in both Her2-
positive and negative cells. The in vitro 
experiments on the Her2-positive cells 
demonstrated substantial staining after incubation 
with nanoparticle/antibody conjugates, while 
minimal staining was found in Her2-negative cells, 
indicating receptor-specific binding of the 
conjugated PLA nanoparticles. Correspondingly, 
the high-resolution ultrasound B-mode images of 
the Her2-positive cells were more gray after 
nanoparticle treatment (133 ± 4 in treated cells 
versus 109 ± 4 in control, p < 0.001, n = 5), while 
no difference was detected in the cells that did not 
overexpress the receptors (117 ± 3 in treated cells 
versus 118 ± 5 in control). Hence the authors 
demonstrated the feasibility of using targeted 
nanoparticles to enhance ultrasonic images in vitro. 
This may be a promising approach to target cancer 
biomarkers for site-specific ultrasound imaging.
27 
 
 
Figure 4: Synthetic scheme for the preparation of USCA developed from biodgradable PLA and 
surface conjugated to anti-Her2 antibodies. Copyrighted from reference
27 
 
In general, Ultrasound imaging offers high spatial 
resolution (<1 mm) and anatomical information. 
33 
Even though, the nanosize of the USCA does not 
contribute much to the imaging, recent instrumental 
advances have been accomplished to overcome 
some of the limitations. An important limitation to 
the use of US imaging is the need of relatively 
large size contrast agent (>500-700 nm), that 
restricts the tissue penetration and thus limit 
applications to vascular targets. Its interobserver 
dependability and the inability to differentiate 
between surrounding and the abnormal tissue are 
some other major limitations of US.  
 
CONCLUSION 
 
An abnormality at a molecular level is extremely 
essential to diagnose at an asymptomatic stage. 
This task now heavily rely on nanoparticles who 
are able to communicate with biomolecules and 
hence found tremendous applications as a 
diagnostic agent.
34 This communication between 
nanoparticles and tissue when decoded can find 
useful applications to understand the anatomical 
aspects of the tissue where the molecular changes 
have occurred. Existing noninvasive, non-ionizing 
diagnostic imaging techniques such as ultrasound 
(US) can serve as a mode to decode these 
communications. Even though the stability of 
nanoparticles for ultrasound imaging is the matter 
of concern, technological advances has enabled the 
use of these unstable nanoparticles for the period of 
time which allows decoding the molecular 
information. However, a relatively large size 
contrast agent for US imaging restricts the tissue 
penetration and thus limit applications to vascular 
targets. Moreover, the development of 
multifunctional particles in which magnetic 
materials can be incorporated into a nanoparticle 
along with the nanobubbles can also assist in the 
use of multimodal techniques such as US and 
MRI.
35 These hybrid forms of imaging via 
incorporating magnetic and optical properties with 
microbubbles may be exploited to increase 
sensitivity and therapeutic potential. Such hybrid 
imaging techniques may improve sensitivity for 
molecular imaging and our ability to characterize 
disease All in all, scientist across the world has 
developed these nanorobots which can, not only, 
evade body’s immune system, but also, assist in the 
diagnosis of various disease states at its onset. 
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